This educational activity focuses on the clinical efficacy, safety profile, and practical implementation of BCMA-targeted bispecific antibodies in the management of relapsed/refractory multiple myeloma (RRMM), highlighting current clinical trial data and best practices for adverse event monitoring and management in clinical practice.

RELEASED DATE: January 06, 2026
EXPIRATION DATE: January 06, 2027

This CME activity will provide practical information to oncologists and hematologists on the use of BCMA-targeted bispecific antibodies for the treatment of relapsed or refractory multiple myeloma, including rationale and patient selection. Expert faculty will review clinical efficacy and safety data from pivotal trials to guide individualized treatment planning. Proactive recognition, grading, and management of immune-related adverse events will be discussed. The program will conclude with a whiteboard animation and case-based discussion to reinforce key strategies for optimizing outcomes.

RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026

This CME-accredited micro-learning activity introduces healthcare professionals to an immersive AR Mobile Application designed to enhance patient-centered care in relapsed/refractory multiple myeloma (R/R MM). Through a brief faculty-led demonstration, learners will explore the practical use of AR technology to reinforce clinical concepts, support shared decision-making, and improve communication with patients and colleagues.

RELEASED DATE: May 30, 2026
EXPIRATION DATE: May 30, 2027